Loading company…
Orange Grove Bio develops treatments targeting neutrophils and immune signaling.
Founded in 2019, Orange Grove Bio develops neutrophil-targeting treatments for diseases involving dysregulated immune signaling, including oncology, inflammatory, and autoimmune conditions. Marc Appel founded the company. In October 2021, IpiNovyx Bio raised USD 10 million in seed funding, with Orange Grove Bio among the participating investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in